NATCO Pharma Limited (NATCOPHARM.NS)
NSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹794.55 (+0.55%) as of
Key statistics
- Market cap
- 146.20B
- P/E (TTM)
- 12.54
- Forward P/E
- 16.77
- EPS (TTM)
- 63.37
- Dividend yield
- 0.75%
- 52-week range
- 773.60 – 1,226.80
- Beta
- 0.15
- Revenue (TTM)
- 34.85B
- Profit margin
- 32.84%
- Analyst target
- ₹1,004.44
- Volume
- 433.37k
About NATCO Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 4,433
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.